Recombinant CD19 (Inebilizumab Biosimilar) 抗体
Research Grade
适用: 人
ELISA
宿主: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原 See all CD19 (Inebilizumab Biosimilar) products
- CD19 (Inebilizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
-
Mammalian Cells
-
克隆类型
- 单克隆
-
标记
- This CD19 (Inebilizumab Biosimilar) antibody is un-conjugated
- 应用范围
- ELISA
- 原理
- Inebilizumab Biosimilar - Anti-CD19 mAb
- 产品特性
- Antibody Type: IgG1-kappa
- 质量等级
- Research Grade
- 亚型
- IgG1 kappa
-
-
- 限制
- 仅限研究用
-
- 缓冲液
- PBS pH 7.5
- 储存条件
- -80 °C
- 储存方法
- store at -80°C
-
- 抗原
- CD19 (Inebilizumab Biosimilar)
- Abstract
- CD19 (Inebilizumab Biosimilar) 产品
- 物质类
- Biosimilar
- 背景
-
MEDI-551
Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody that targets the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, which may be usefull to treat neuromyelitis optica spectrum disorder (NMOSD)through B-cell depletion. - CAS-编号
- 1299440-37-1
-
You are here:
